

# Preetesh Jain

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8490626/publications.pdf>

Version: 2024-02-01

156  
papers

4,536  
citations

117453

34  
h-index

123241

61  
g-index

157  
all docs

157  
docs citations

157  
times ranked

5801  
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. <i>Blood</i> , 2015, 125, 2062-2067.	0.6	303
2	Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. <i>Lancet Haematology</i> , 2015, 2, e186-e193.	2.2	227
3	<i>TP53</i> mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. <i>Cancer</i> , 2016, 122, 3484-3491.	2.0	200
4	Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. <i>American Journal of Hematology</i> , 2019, 94, 710-725.	2.0	151
5	Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. <i>Leukemia and Lymphoma</i> , 2015, 56, 1643-1650.	0.6	130
6	Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. <i>Blood</i> , 2013, 121, 4867-4874.	0.6	124
7	Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. <i>Blood</i> , 2016, 127, 1269-1275.	0.6	119
8	Chronic lymphocytic leukemia (CLL) then and now. <i>American Journal of Hematology</i> , 2016, 91, 330-340.	2.0	116
9	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. <i>Cancer</i> , 2017, 123, 4391-4402.	2.0	114
10	Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 118, 5201-5210.	0.6	110
11	Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. <i>Cancer</i> , 2017, 123, 2268-2273.	2.0	103
12	Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. <i>Cancer</i> , 2016, 122, 2857-2866.	2.0	88
13	Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. <i>Blood Advances</i> , 2019, 3, 851-861.	2.5	88
14	Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. <i>Lancet Haematology</i> , 2015, 2, e376-e383.	2.2	86
15	Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. <i>British Journal of Haematology</i> , 2018, 183, 578-587.	1.2	81
16	Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. <i>British Journal of Haematology</i> , 2016, 174, 760-766.	1.2	76
17	HyperCVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. <i>American Journal of Hematology</i> , 2018, 93, 91-99.	2.0	74
18	Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. <i>Cancer</i> , 2019, 125, 559-574.	2.0	70

#	ARTICLE	IF	CITATIONS
19	Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells. <i>Molecular Cancer Research</i> , 2015, 13, 944-953.	1.5	67
20	Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. <i>Leukemia</i> , 2019, 33, 2762-2766.	3.3	67
21	Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. <i>Haematologica</i> , 2012, 97, 599-607.	1.7	65
22	Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. <i>Lancet Haematology</i> , 2015, 2, e118-e128.	2.2	65
23	Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. <i>Blood Advances</i> , 2020, 4, 2927-2938.	2.5	61
24	Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. <i>British Journal of Haematology</i> , 2017, 178, 403-412.	1.2	57
25	Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study. <i>Mycoses</i> , 2019, 62, 1140-1147.	1.8	57
26	Recent advances in de novo CD5 <sup>+</sup> diffuse large B cell lymphoma. <i>American Journal of Hematology</i> , 2013, 88, 798-802.	2.0	55
27	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. <i>American Journal of Hematology</i> , 2020, 95, 623-629.	2.0	54
28	The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. <i>Leukemia</i> , 2014, 28, 973-975.	3.3	52
29	Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). <i>British Journal of Haematology</i> , 2018, 182, 404-411.	1.2	50
30	Mantle cell lymphoma in 2022 - A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. <i>American Journal of Hematology</i> , 2022, 97, 638-656.	2.0	48
31	Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 2154-2158.	3.2	47
32	Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). <i>Annals of Oncology</i> , 2017, 28, 1554-1559.	0.6	44
33	STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. <i>Oncotarget</i> , 2018, 9, 21268-21280.	0.8	44
34	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. <i>Blood Advances</i> , 2020, 4, 1038-1050.	2.5	43
35	Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. <i>Leukemia</i> , 2018, 32, 353-363.	3.3	36
36	Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. <i>Leukemia and Lymphoma</i> , 2014, 55, 2879-2886.	0.6	35

#	ARTICLE	IF	CITATIONS
37	Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. <i>Nature Communications</i> , 2021, 12, 2877.	5.8	35
38	Chronic Myeloid Leukemia: Overview of New Agents and Comparative Analysis. <i>Current Treatment Options in Oncology</i> , 2013, 14, 127-143.	1.3	34
39	Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 202-212.	0.8	34
40	The absolute percent deviation of <i>IGHV</i> mutation rather than a 98% cutoff predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. <i>British Journal of Haematology</i> , 2018, 180, 33-40.	1.2	33
41	Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. <i>British Journal of Haematology</i> , 2021, 192, e38-e42.	1.2	33
42	Richter's transformation in chronic lymphocytic leukemia. <i>Oncology</i> , 2012, 26, 1146-52.	0.4	32
43	Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. <i>Cancer</i> , 2016, 122, 238-248.	2.0	30
44	Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. <i>Haematologica</i> , 2013, 98, 1686-1688.	1.7	29
45	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. <i>Blood Cancer Discovery</i> , 2022, 3, 385-393.	2.6	29
46	Mutated <i>NPM1</i> in patients with acute myeloid leukemia in remission and relapse. <i>Leukemia and Lymphoma</i> , 2014, 55, 1337-1344.	0.6	28
47	Update on the Biology and Treatment Options for Hairy Cell Leukemia. <i>Current Treatment Options in Oncology</i> , 2014, 15, 187-209.	1.3	27
48	Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. <i>Journal of Clinical Oncology</i> , 2015, 33, 1557-1563.	0.8	27
49	Durable remission with rituximab in a patient with an unusual variant of <i>C</i> astleman's disease with myelofibrosis-TAFRO syndrome. <i>American Journal of Hematology</i> , 2015, 90, 1091-1092.	2.0	26
50	Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 152-162.	0.2	25
51	Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. <i>International Journal of Hematology</i> , 2019, 109, 545-552.	0.7	25
52	Clinical and molecular characteristics of <i>XPO1</i> mutations in patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016, 91, E478-E479.	2.0	24
53	Biclonal <i>IGHV</i> hairy cell leukemia variant and CLL -successful treatment with ibrutinib and venetoclax. <i>American Journal of Hematology</i> , 2018, 93, 1568-1569.	2.0	24
54	Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly. <i>Blood</i> , 2012, 120, 2768-2769.	0.6	23

#	ARTICLE	IF	CITATIONS
55	Prediction for sustained deep molecular response of <i>BCR-ABL1</i> levels in patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2018, 124, 1160-1168.	2.0	23
56	High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management. <i>Journal of Clinical Oncology</i> , 2020, 38, 4302-4316.	0.8	22
57	Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients ( $\geq 65$ years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 406-415.	5.1	22
58	Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 169-182.	1.4	21
59	Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , 2014, 123, 1424-1426.	0.6	21
60	Phase II study of methotrexate, vincristine, pegylated asparaginase, and dexamethasone (MOAD) in patients with relapsed/refractory acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2015, 90, 120-124.	2.0	21
61	Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome. <i>Leukemia Research</i> , 2017, 59, 105-109.	0.4	21
62	Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias (De novo and blast phase) <i>TJ ETQq0 0,0 rgBT /Overlock 10</i>	2.0	20
63	Chronic Lymphocytic Leukemia With Central Nervous System Involvement: A High-Risk Disease?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 338-341.	0.2	19
64	Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. <i>British Journal of Haematology</i> , 2016, 173, 114-126.	1.2	19
65	The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. <i>American Journal of Hematology</i> , 2021, 96, 241-250.	2.0	19
66	Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. <i>Molecular Cancer Research</i> , 2017, 15, 610-618.	1.5	18
67	Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. <i>Lancet Haematology</i> , the, 2017, 4, e67-e74.	2.2	18
68	<i>TP53</i> mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. <i>Cancer</i> , 2017, 123, 3717-3724.	2.0	18
69	Activation of the B-cell receptor successively activates NF- $\kappa$ B and STAT3 in chronic lymphocytic leukemia cells. <i>International Journal of Cancer</i> , 2017, 141, 2076-2081.	2.3	17
70	Blastoid Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 941-956.	0.9	17
71	STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. <i>Journal of Immunology</i> , 2019, 203, 3078-3085.	0.4	16
72	Advances in the assessment of minimal residual disease in mantle cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 127.	6.9	16

#	ARTICLE	IF	CITATIONS
73	Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytes. <i>Immunologic Research</i> , 2015, 63, 216-227.	1.3	15
74	Neoadjuvant chemotherapy or chemoradiotherapy in head and neck cancer. <i>Indian Journal of Cancer</i> , 2008, 45, 83.	0.2	15
75	Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium. <i>Blood</i> , 2021, 138, 744-744.	0.6	15
76	A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2016, 122, 3336-3343.	2.0	14
77	Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2686-2691.	0.6	14
78	Zoledronic acid induced osteonecrosis of tibia and femur. <i>Indian Journal of Cancer</i> , 2009, 46, 249.	0.2	13
79	CD4 <sup>+</sup> /CD8 <sup>+</sup> Variant of T-Cell Large Granular Lymphocytic Leukemia or Hepatosplenic T-Cell Lymphoma: A Clinicopathologic Dilemma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 610-613.	0.2	13
80	Novel therapeutic options for relapsed hairy cell leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2264-2272.	0.6	13
81	Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e47-e49.	0.2	12
82	Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. <i>Annals of Hematology</i> , 2018, 97, 1183-1191.	0.8	12
83	Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma. <i>Blood Advances</i> , 2019, 3, 2035-2039.	2.5	12
84	Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≥ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial. <i>Blood</i> , 2019, 134, 3987-3987.	0.6	12
85	Multiple myeloma with paraneoplastic leucocytoclastic vasculitis. <i>Indian Journal of Cancer</i> , 2009, 46, 173.	0.2	11
86	Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 616-624.	0.2	11
87	Relapsed Refractory BRAF-Negative, IGHV4-34 <sup>+</sup> Positive Variant of Hairy Cell Leukemia: A Distinct Entity?. <i>Journal of Clinical Oncology</i> , 2016, 34, e57-e60.	0.8	11
88	First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). <i>Leukemia and Lymphoma</i> , 2020, 61, 445-449.	0.6	11
89	BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner. <i>Current Oncology Reports</i> , 2022, 24, 1299-1311.	1.8	10
90	Numb chin syndrome by precursor B acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2014, 89, 860-861.	2.0	9

#	ARTICLE	IF	CITATIONS
91	Advances in the Clinical Staging of Chronic Lymphocytic Leukemia. <i>Clinical Chemistry</i> , 2011, 57, 1771-1772.	1.5	8
92	“Cup-like” blasts and NPM1 and FLT3 (ITD) mutations in acute myeloid leukemia (AML). <i>International Journal of Hematology</i> , 2013, 98, 3-3.	0.7	8
93	Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2015, 90, 752-753.	2.0	8
94	Clinical characteristics and outcomes of previously untreated patients with adult onset acute lymphoblastic leukemia and acute lymphoblastic lymphoma with hyper-CVAD based regimens. <i>American Journal of Hematology</i> , 2017, 92, E595-E597.	2.0	8
95	Synchronous presentation of intra-nodal follicular dendritic cell sarcoma and Castleman disease. <i>American Journal of Hematology</i> , 2017, 92, 478-479.	2.0	8
96	PET-positive lymphadenopathy in CLL? Not always Richter transformation. <i>American Journal of Hematology</i> , 2017, 92, 405-406.	2.0	8
97	STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells. <i>Oncotarget</i> , 2018, 9, 33710-33718.	0.8	8
98	Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-2 Clinical Trial. <i>Blood</i> , 2021, 138, 3525-3525.	0.6	8
99	Chronic myeloid leukemia presenting as paraneoplastic ocular myasthenia gravis. <i>Annals of Oncology</i> , 2007, 18, 804-805.	0.6	7
100	Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts. <i>Haematologica</i> , 2013, 98, e141-e142.	1.7	7
101	Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multicentre propensity score-matched study. <i>British Journal of Haematology</i> , 2020, 191, 806-815.	1.2	7
102	Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma. <i>Blood</i> , 2021, 137, 1124-1129.	0.6	7
103	EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. <i>Modern Pathology</i> , 2021, 34, 2183-2191.	2.9	7
104	Zanubrutinib in lymphoproliferative disorders: a comprehensive review. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210939.	1.1	7
105	An Unusual Case of Aggressive Systemic Mastocytosis With Associated Refractory Plasma Cell Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 459-462.	0.2	6
106	FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. <i>Cancer</i> , 2014, 120, 3494-3501.	2.0	6
107	High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome. <i>American Journal of Hematology</i> , 2015, 90, 471-477.	2.0	6
108	CLL progression after one cycle of FCR: Richter's transformation versus EBV-associated lymphoproliferation. <i>American Journal of Hematology</i> , 2017, 92, 1113-1114.	2.0	6

#	ARTICLE	IF	CITATIONS
109	Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. American Journal of Hematology, 2021, 96, E137-E140.	2.0	6
110	STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. Journal of Immunology, 2022, 208, 2847-2855.	0.4	6
111	Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. Haematologica, 2016, 101, e324-e327.	1.7	5
112	FDG PET/CT in Malignant Eccrine Spiradenoma. Clinical Nuclear Medicine, 2017, 42, 125-126.	0.7	5
113	Spontaneous remission of chemo-immunotherapy related, non-transplant Epstein-Barr virus-associated lymphoproliferative disorder in a patient with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 2540-2542.	0.6	4
114	Aspergillus pseudomembranous necrotizing tracheitis. American Journal of Hematology, 2013, 88, 242-242.	2.0	4
115	Primary autoimmune myelofibrosis (MF) with high-grade peripheral T-cell lymphoma (PTCL) NOS. European Journal of Haematology, 2013, 91, n/a-n/a.	1.1	4
116	Richter's syndrome - update on biology and management. Expert Opinion on Orphan Drugs, 2014, 2, 453-463.	0.5	4
117	STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget, 2021, 12, 401-411.	0.8	4
118	Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma. Leukemia and Lymphoma, 2021, 62, 1325-1334.	0.6	4
119	Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib. Blood, 2018, 132, 4151-4151.	0.6	4
120	Mantle cell lymphoma involving tonsils: a clinicopathologic study of 83 cases. Human Pathology, 2021, 118, 60-68.	1.1	4
121	Flower cells of leukemia. Blood, 2010, 115, 1668-1668.	0.6	3
122	Central nervous system Richter's transformation and parvovirus B19 infection. Leukemia and Lymphoma, 2013, 54, 2070-2072.	0.6	3
123	Multiple recurrent extramedullary relapses of high-grade diffuse large B-cell lymphoma presenting in acute leukemic phase. American Journal of Hematology, 2013, 88, 433-434.	2.0	3
124	Richter's transformation in CLL - a distinct lymphoma. Nature Reviews Clinical Oncology, 2014, 11, 6-8.	12.5	3
125	Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations. American Journal of Hematology, 2016, 91, 354-355.	2.0	3
126	TET2, DNMT3A, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. Leukemia and Lymphoma, 2016, 57, 1969-1973.	0.6	3



#	ARTICLE	IF	CITATIONS
127	Response to pembrolizumab and lenalidomide in advanced refractory mycosis fungoides. <i>Leukemia and Lymphoma</i> , 2019, 60, 1079-1082.	0.6	3
128	Carcinocythemia—Cancer cell leukemia. <i>American Journal of Hematology</i> , 2021, 96, 397-398.	2.0	3
129	A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, E243-E246.	2.0	3
130	Disseminated cytomegalovirus-associated hemophagocytic lymphohistiocytosis in an elderly patient. <i>Blood Research</i> , 2016, 51, 288.	0.5	2
131	Mixed angioinvasive exserohilum and scedosporium infection in a patient with AML. <i>American Journal of Hematology</i> , 2017, 92, 119-120.	2.0	2
132	A case of lymphocytic variant hypereosinophilic syndrome with sub-diagnostic systemic mastocytosis. <i>Blood Research</i> , 2017, 52, 71.	0.5	2
133	Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As <sub>2</sub> O <sub>3</sub> ) and all-trans retinoic acid (ATRA). <i>Blood Research</i> , 2018, 53, 169.	0.5	2
134	Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 3172-3180.	0.6	2
135	Triple hit SOX11 <sup>+</sup> , MME <sup>+</sup> , TP53 mutated high grade pleomorphic mantle cell lymphoma. <i>American Journal of Hematology</i> , 2021, 96, 165-166.	2.0	2
136	Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib Era: Comprehensive Analysis of 168 Patients. <i>Blood</i> , 2018, 132, 1599-1599.	0.6	2
137	Clinico-Pathological Characteristics, Treatments and Outcomes of Patients with Dendritic Cell Sarcoma (DS). <i>Blood</i> , 2015, 126, 2700-2700.	0.6	2
138	Overview of recent developments in chronic lymphocytic leukemia. <i>South Asian Journal of Cancer</i> , 2012, 01, 84-89.	0.2	2
139	Phase I/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, E232-E235.	2.0	2
140	Computer-aided detection of mantle cell lymphoma on F-FDG PET/CT using a deep learning convolutional neural network. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 260-270.	1.0	2
141	Sequential Lymphomas or Clonally Unrelated Richter Syndrome of Chronic Lymphocytic Leukemia Into Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 606-609.	0.2	1
142	Late extramedullary recurrence of adult onset Burkitt's lymphoma mimicking peritoneal carcinomatosis. <i>American Journal of Hematology</i> , 2013, 88, 920-921.	2.0	1
143	Philadelphia—positive dimorphic blasts in mixed phenotype acute leukemia with TET2 mutation. <i>American Journal of Hematology</i> , 2016, 91, 647-648.	2.0	1
144	Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. <i>British Journal of Haematology</i> , 2018, 182, 718-723.	1.2	1

#	ARTICLE	IF	CITATIONS
145	Patterns of imatinib resistance mutation analysis in chronic myeloid leukemia (CML) patients on imatinib at the time of loss of response to the drug in Asian Indian subjects. <i>Journal of Clinical Oncology</i> , 2009, 27, 7079-7079.	0.8	1
146	Newer therapeutic molecules for multiple myeloma. <i>Indian Journal of Cancer</i> , 2008, 45, 142.	0.2	1
147	Lymphoma masquerading as acute leukemia-mystery unfolded. <i>Indian Journal of Cancer</i> , 2010, 47, 222.	0.2	0
148	Cytoplasmic globules in erythroid blasts and CLL. <i>Blood</i> , 2013, 121, 3305-3305.	0.6	0
149	Atypical chronic lymphocytic leukemia with polyglandular autoimmune endocrinopathy type II: a complex profile. <i>Leukemia and Lymphoma</i> , 2014, 55, 944-946.	0.6	0
150	Hodgkin's Lymphoma Presenting as a Cavitory Lung Mass. <i>American Journal of the Medical Sciences</i> , 2017, 354, 441.	0.4	0
151	Rater. <i>Journal of Clinical Oncology</i> , 2009, 27, e20678-e20678.	0.8	0
152	Characteristics, Outcome and Pattern of Mutations in Patients with Follicular Lymphoma Who Progressed on BTK Inhibitors (Ibrutinib and acalabrutinib). <i>Blood</i> , 2016, 128, 2975-2975.	0.6	0
153	Prognostic Factors, Outcomes and Clinical Characteristics in Patients with Transformed Follicular Lymphoma (t-FL): Cohort Study of 172 Patients. <i>Blood</i> , 2018, 132, 1600-1600.	0.6	0
154	Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R2) in Previously Untreated Follicular Lymphoma. <i>Blood</i> , 2018, 132, 1594-1594.	0.6	0
155	Unravelling the Heterogeneity of Mantle Cell Lymphoma Ecosystem By Single Cell RNA Sequencing. <i>Blood</i> , 2018, 132, 4118-4118.	0.6	0
156	Overall Survival, Adverse Events, and Economic Burden in Medicare-Insured Patients with Mantle Cell Lymphoma Receiving Cancer-Directed Therapy. <i>Blood</i> , 2019, 134, 63-63.	0.6	0